Cytograft.com
is available for sale
Hear how it Cytograft.com sounds
About Cytograft.com
Former one word, exceptionally brandable .com domain representing a company that will revolutionize regenerative medicine by developing a new paradigm in cardiovascular repair that uses cell-based therapies.
Exclusively on Odys Marketplace
€1,440
What's included:
Domain name Cytograft.com
Become the new owner of the domain in less than 24 hours.
Complimentary Logo Design
Save time hiring a designer by using the existing high resolution original artwork, provided for free by Odys Global with your purchase.
Built-In SEO
Save tens of thousands of dollars and hundreds of hours of outreach by tapping into the existing authority backlink profile of the domain.
Free Ownership Transfer
Tech Expert Consulting
100% Secure Payments
Premium Aged Domain Value
Seen In
Age
Traffic
SEO Metrics
Own this Domain in 3 Easy Steps
With Odys, buying domains is easy and safe. Your dream domain is just a few clicks away.
.1
Buy your Favorite Domain
Choose the domain you want, add it to your cart, and pay with your preferred method.
.2
Transfer it to your Registrar
Follow our instructions to transfer ownership from the current registrar to you.
.3
Get your Brand Assets
Download the available logos and brand assets and start building your dream website.
Trusted by the Top SEO Experts and Entrepreneurs
Rachel Parisi
★ ★ ★ ★ ★
I purchased another three aged domains from Odys in a seamless and painless transaction. John at Odys was super helpful! Odys is my only source for aged domains —you can trust their product.
Stefan
★ ★ ★ ★ ★
Odys is absolutely the best premium domain marketplace in the whole internet space. You will not go wrong with them.
Adam Smith
★ ★ ★ ★ ★
Great domains. Great to deal with. In this arena peace of mind can be difficult to come by, but I always have it with Odys and will continue to use them and recommend them to colleagues and clients.
Brett Helling
★ ★ ★ ★ ★
Great company. Very professional setup, communication, and workflows. I will definitely do business with Odys Global moving forward.
Larrian Gillespie Csi
★ ★ ★ ★ ★
I have bought 2 sites from Odys Global and they have both been of high quality with great backlinks. I have used one as the basis for creating a new site with a great DR and the other is a redirect with again high DR backlinks. Other sites I have looked through have low quality backlinks, mostly spam. I highly recommend this company for reliable sites.
Henry Fox
★ ★ ★ ★ ★
Great company!
Vijai Chandrasekaran
★ ★ ★ ★ ★
I’ve bought over 30 domains from Odys Global in the last two years and I was always very satisfied. Besides great quality, niche-specific auction domains, Alex also helped me a lot with SEO and marketing strategies. Auction domains are not cheap, but quality comes with a price. If you have the budget and a working strategy, these domains will make you serious money.
Keith
★ ★ ★ ★ ★
Earlier this year, I purchased an aged domain from Odys as part of a promo they’re running at the time. It was my first experience with buying an aged domain so I wanted to keep my spend low. I ended up getting a mid level DR domain for a good price. The domain had solid links from niche relevant high authority websites. I used the site as a 301 redirect to a blog I had recently started. Within a few weeks I enjoyed new traffic levels on my existing site. Happy to say that the Odys staff are friendly and helpful and they run a great business that is respected within the industry.
BioMedical Engineering Team
Dr. Todd McAllister, Ph.D. - Co-Founder and CEO of Cytograft Tissue Engineering
Dr. McAllister received his Ph.D. in BioMedical Engineering from the University of California, San Diego. He is the co-founder and CEO of Cytograft Tissue Engineering, Inc. Dr. McAllister has been an early proponent of biological approaches to tissue engineering that do not require synthetic scaffolds. Dr. McAllister has also pioneered a novel business strategy within Regenerative Medicine, taking Cytograft’s lead product, the Lifeline™ Vascular Graft from inception to commercial licensure in Europe on less than $10M in private equity.
Dr. McAllister also served as Co-Director of the Center for Regenerative Medicine at the St. Joseph’s Translational Research Institute in Atlanta, where he oversaw a broader range of cell-based cardiovascular repair technologies. He also serves on several advisory boards, including Lumen, Biocardia, and the Medical University of South Carolina.
Dr. Nicolas L'Heureux, Ph.D. - Co-Founder and CSO of Cytograft Tissue Engineering
Dr. L’Heureux received his Ph.D. in Cell Biology from Laval University in Quebec, Canada and was a post-doctoral AHA fellow in the Department of Bioengineering at the University of California, San Diego. He is the co-founder and CSO of Cytograft Tissue Engineering, Inc. Dr. L'Heureux invented Tissue Engineering by Self-Assembly (TESA), a novel tissue engineering strategy. He advocates a biological approach to Regenerative Medicine, minimizing the inclusion of synthetic scaffolds and exogenous biomaterials.
Dr. L'Heureux also served as Co-Director of the Center for Regenerative Medicine at the St. Joseph’s Translational Research Institute in Atlanta. As a co-director he oversaw research of cell-based cardiovascular repair technologies.
Dr. Nathalie Dusserre, Ph.D. - Vice President of Manufacturing and Regulatory Affairs of Cytograft Tissue Engineering
Dr. Dusserre received her Ph.D. in Cell Biology and Microbiology from Claude Bernard University in Lyon, France. She was a post-doctoral fellow at the Infectious Diseases Research Center at Laval University in Quebec Canada and a postgraduate researcher in the Department of Bioengineering at the University of California, San Diego.
As the Vice President of Manufacturing and Regulatory Affairs at Cytograft Tissue Engineering, Dr. Dusserre oversees all regulatory aspects of Cytograft's operations. Under her leadership, Cytograft has successfully acquired commercial licensure in Germany and clinical licensure in Poland, Slovakia and the United Kingdom. She is also currently leading interactions with the FDA regarding the recent submission of an IND application for LifeLine™. In addition to her regulatory role, Dr. Dusserre also manages Cytograft's manufacturing and research teams.
February 16, 2020 at 6:36 PM
KP
Kiril Papaz
May 20, 2014 – Dr. L'Heureux to be the keynote speaker at the French National Meeting on Biomaterials Research ("Assises Nationales de la Recherche en Biomatériaux"; Autrans, France).
May 5, 2014 - Dr. McAllister to present Cytograft’s unique and successful business model at the Regenerative Medicine conference in San Francisco. Program details can be found here.
April 27, 2014 – Dr. L'Heureux to present recent results regarding the use of "Cell-synthesized extracellular matrix particles for tissue engineering and aesthetic applications" at the Experimental Biology 2014 meeting in San Diego. Link to the published abstract in the FASEB Journal here.
April 25, 2014 - Dr. McAllister to present on the convergence of tissue engineering and bioprinting at the ISCT annual meeting. Meeting agenda is here.
March 16, 2014 – Dr. McAllister publishes a perspective manuscript in MedNous. Full text is available here.
March 14, 2014 – A patent application describing the new abdominal aorta aneurism (AAA) repair device created by Cytograft is published by the USPTO (Patent application 20140081385)
March 14, 2014 – Dr. L'Heureux to speak at the INSERM Workshop #226 "3D cell culture bridges the gap between cell culture and live tissue" (Bordeaux, France).
March 14, 2014 - Dr. McAllister presents data in an invited lecture at the Ohio State University wound Care Conference. Conference program can be found here.
October 28, 2013 – Dr. L’Heureux to hold a seminar at the Vascular Surgery Institute of Fudan University Medical School (Shanghai, China).
October 7, 2013 - Results from the "First human use of an allogeneic tissue-engineered vascular graft for hemodialysis access" are published in the Journal of Vascular Surgery (available as Epub ahead of print). Link to publisher here.
December 5, 2013 - Drs. L’Heureux and McAllister publish in the 2012 World Stem Cell Report. In this invited manuscript, Cytograft’s founders propose revised regulatory standards for autologous cell therapies. See the full length manuscript in Regenerative Medicine here.